Your browser doesn't support javascript.
loading
Role of PARP inhibitors in cancer biology and therapy.
Davar, D; Beumer, J H; Hamieh, L; Tawbi, H.
Afiliación
  • Davar D; Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Curr Med Chem ; 19(23): 3907-21, 2012.
Article en En | MEDLINE | ID: mdl-22788767
ABSTRACT
Deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncology heralded the clinical development of poly(ADP-ribose) polymerase (PARP) inhibitors. Although initially developed to exploit synthetic lethality in models of cancer associated with defective DNA repair, our burgeoning knowledge of PARP biology has resulted in these agents being exploited both in cancer with select chemotherapeutic agents and in non-malignant diseases. In this review article, we briefly review the mechanisms of DNA repair and pre-clinical development of PARP inhibitors before discussing the clinical development of the various PARP inhibitors in depth.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores Enzimáticos / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Neoplasias Límite: Humans Idioma: En Revista: Curr Med Chem Asunto de la revista: QUIMICA Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores Enzimáticos / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Neoplasias Límite: Humans Idioma: En Revista: Curr Med Chem Asunto de la revista: QUIMICA Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos